Keywords: hemophilia; factor VIII inhibitor; coagulopathy; FEIBA; cardiopulmonary bypass;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: CPB; cardiopulmonary bypass; FEIBA; factor eight inhibitor bypassing activity; 4F; four factor; FFP; fresh frozen plasma; INR; international normalized ratio; PCC; prothrombin complex concentrate; ROTEM; rotational thromboelastometry; TEG; thromboelastogr
Keywords: 23.1; 41.1; 35; ASA; acetyl salicylic acid; BMI; body mass index; CABG; coronary artery bypass graft; CPB; cardiopulmonary bypass; CryoPPT; cryoprecipitate; FEIBA; factor 8 inhibitor bypassing activity; FFP; fresh frozen plasma; MI; myocardial infarction;
Keywords: dabigatran; intracerebral hemorrhage; anticoagulation reversal; FEIBA; ischemic stroke;
Keywords: 21; 37; FEIBA; factor VIII inhibitor bypassing activity; LVAD; left ventricular assist device; PCC; prothrombin complex concentrates;
Keywords: Anticoagulants/Administration and Dosage; Atrial Fibrillation; Drug Administration Schedule; Drug Monitoring; Thrombosis/Drug Therapy; Endoscopy; Gastrointestinal; AF; atrial fibrillation; aPTT; activated partial thromboplastin time; CrCl; creatinine clea
Treatment tailoring for factor V deficient patients and perioperative management using global hemostatic coagulation assays
Keywords: FV deficiency; Thrombin generation; ROTEM; rFVIIa; FEIBA; Global coagulation assays;
Factor Eight Inhibitor Bypassing Agent (FEIBA) for Reversal of Target-Specific Oral Anticoagulants in Life-Threatening Intracranial Bleeding
Keywords: FEIBA; target-specific oral anticoagulants; life-threatening bleeding; dabigatran; rivaroxaban; apixaban; intracranial hemorrhage; anti-xa inhibitor; anticoagulation; reversal;
Ex vivo reversal of the anticoagulant effects of edoxaban
Keywords: aPTT; Activated partial thromboplastin time; Cmax; Maximum plasma concentration; FEIBA; Factor VIII inhibitor bypass activity; FEU; Fibrinogen equivalent units; FX; Factor X; FXa; Factor Xa; LMWH; Low-molecular-weight heparin; NOACs; Novel oral anticoagul
Immune tolerance induction using a factor VIII/von Willebrand factor concentrate (BIOSTATE®), with or without immunosuppression, in Australian paediatric severe haemophilia A patients with high titre inhibitors: A multicentre, retrospective study
Keywords: AE; Adverse event; BU; Bethesda units; CR; Complete response; CVAD; Central venous access device; F; Failed ITI; FEIBA; FVIII inhibitor bypassing activity; FVIII; Factor VIII; HTC; Haemophilia treatment centre; I-ITI; International Immune Tolerance study;
Reversal of New, Factor-specific Oral Anticoagulants by rFVIIa, Prothrombin Complex Concentrate and Activated Prothrombin Complex Concentrate: A Review of Animal and Human Studies
Keywords: AF; atrial fibrillation; aPCC; activated prothrombin complex concentrates; BID; twice daily; Cmax; maximal plasma concentration; F; coagulation factor; FEIBA; factor eight inhibitor bypass activity; PCC; prothrombin complex concentrates; rFVIIa; activated
Total Knee Arthroplasty in a Patient With Hemophilic Arthropathy and High-Titer Inhibitors
Keywords: hemophilic arthropathy; FEIBA; knee replacement; cost analysis; factor VIII inhibitors;
Fondaparinux - data on efficacy and safety in special situations
Keywords: ACS; acute coronary syndrome; anti-Xa; anti-factor Xa activity; APS; antiphospholipid syndrome; BID; twice a day; BMI; body mass index; DVT; deep vein thrombosis; EMA; European Medicines Agency; FDA; U.S. Food and Drug Administration; FEIBA; factor eight